Bimiralisib (PQR309)
Actinic Keratosis
About Torqur
Torqur AG is a private, clinical-stage biotechnology company based in Zurich, Switzerland, developing targeted cancer therapies. Its core platform centers on creating a portfolio of disease-specific inhibitors of the PI3K/mTOR pathway, a key driver in many cancers. The lead asset, bimiralisib, is in Phase 2 development for actinic keratosis and other indications, with promising early clinical data. The company is a subsidiary of the Swiss Rockets incubator and is led by a board with deep expertise in oncology drug development and business.
View full company profileAbout Torqur
Torqur AG is a private, clinical-stage biotechnology company based in Zurich, Switzerland, developing targeted cancer therapies. Its core platform centers on creating a portfolio of disease-specific inhibitors of the PI3K/mTOR pathway, a key driver in many cancers. The lead asset, bimiralisib, is in Phase 2 development for actinic keratosis and other indications, with promising early clinical data. The company is a subsidiary of the Swiss Rockets incubator and is led by a board with deep expertise in oncology drug development and business.
View full company profileTherapeutic Areas
Other Actinic Keratosis Drugs
| Drug | Company | Phase |
|---|---|---|
| 15dPMJ2 | Claradele Pharmaceuticals | Pre-clinical |
| Skinject Patch | Skinject | Research |
| RLS-1496 | Rubedo Life Sciences | Phase 1 |
| VD-001 | Vidac Pharma | Phase 2B |
| Klisyri (tirbanibulin) | Almirall | Marketed |